2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：195615-83-9 Product Name： Synonyms：1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;AE37;AE38;AVex-73 EINEC: Molecular Formula：C19H23NO Molecular Weight：281.392
Target:
In Vivo
Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1]. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1]. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1]. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1]. Animal Model: Female Mecp2tm1.1Bird/J HET (C57 background) mice[1] Dosage: 10 mg/kg, 30 mg/kg Administration: Oral administration, daily, for 6.5 weeks Result: Reverse the deficits observed in the HET animals.
In Vitro
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
